Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004496 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure
A Phase 1 study of Acute Renal Failure, sponsored by University of Texas.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT00004496: Completed Phase 1 study of Acute Renal Failure, sponsored by University of Texas.
NCT00004496 is a Phase 1 study of Acute Renal Failure that has completed, run by University of Texas. The registered enrollment target is 45 participants, below the 259-participant average among 5 other Acute Renal Failure trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004496, a Phase 1 study of Acute Renal Failure, has completed, sponsored by University of Texas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
OBJECTIVES: I. Determine the maximum tolerated dose and safety of alpha-melanocyte stimulating hormone (alpha-MSH) in patients with acute renal failure. II. Determine the safety and pharmacokinetics of alpha-MSH in patients at high risk of acute renal failure after renal transplantation. III. Determine the safety and pharmacokinetics of alpha-MSH in patients with established ischemic acute renal failure. IV. Determine the effect of alpha-MSH on interleukin-10 pharmacokinetics.
Conditions Studied
Interventions
- DRUG alpha-melanocyte stimulating hormone
Study Locations (2)
Texas
- University of Texas Southwestern Medical Center at Dallas - Dallas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1999-02 |
| Est. Completion | 2003-09 |
| Phase | Phase 1 |
What the finished NCT00004496 record still lists
NCT00004496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 259-participant average among 5 other Acute Renal Failure trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Acute Renal Failure appearing as the primary indexed condition, and to 1 intervention - of which alpha-melanocyte stimulating hormone is the first listed.
NCT00004496 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00004496 about?
NCT00004496 is a clinical study titled "Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure". OBJECTIVES: I. Determine the maximum tolerated dose and safety of alpha-melanocyte stimulating hormone (alpha-MSH) in patients with acute renal failure. II. Determine the safety and pharmacokinetics of alpha-MSH in patients at high risk of acute renal failure after renal transplantation. III. Dete...
What is the current status of trial NCT00004496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 1999-02. Estimated completion is 2003-09.
What conditions does trial NCT00004496 study?
This clinical trial studies the following conditions: Acute Renal Failure.
What interventions are being tested in trial NCT00004496?
The interventions under investigation include: alpha-melanocyte stimulating hormone (DRUG).
Who is sponsoring clinical trial NCT00004496?
This trial is sponsored by University of Texas, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004496 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Renal Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kidney Precision Medicine Project
RECRUITING
-
Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol
COMPLETED · Phase 2
-
Acute Renal Failure Post Liver Transplantation
COMPLETED · NA
-
Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?
COMPLETED · NA
-
Low Dose Thymoglobin in Renal Transplant Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia